Get notified when TPST files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern Doubt (new) — The company has disclosed substantial doubt about its ability to continue as a going concern, a new red flag not present in the prior year.
- Going Concern Doubt (new) — The company has disclosed substantial doubt about its ability to continue as a going concern due to limited cash and uncertainty about obtaining additional funding.
- Going Concern Doubt (new) — The Company has disclosed substantial doubt about its ability to continue as a going concern, a new red flag not present in the prior year.
Tempest Therapeutics reduced its net loss by 37.2% to $26.3M in 2025, but disclosed substantial doubt about its ability to continue as a going concern.
Filed March 30, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 27, 2025 · ~1 min read
Key Changes
-
high
Research and development expense decreased 55.7% to $12.6M, which the company attributes to re-prioritizing efforts towards exploring strategic alternatives.
-
high
In February 2026, the company completed the acquisition of a portfolio of dual-targeting CAR-T product candidates, issuing 8,268,495 shares of our common stock.
-
medium
The company repaid its Oxford Loan in full in April 2025, eliminating the $6.4M balance outstanding at the end of 2024.
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade TPST commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify